I probably didn't explain my point well enough; hence, you missed it.
The Accounts Receivable have to be paid. Money has to be raised to pay the receivables. So they have to sell shares to raise money to pay the bills. As a vendor, Advent is willing to take some of their payment in shares. That is a good thing, because many vendors on this planet are not willing to take shares as payment from a biotech without a revenue stream. And if Advent wasn't taking shares as payment, then they would want cash, so Northwest would have to sell those same shares for cash to those willing and able to buy them from the company. So in the end, it's the same number of shares going out the door.
So the "massive dilution" you reference is the SAME, whether Advent is paid in shares, or someone buys the shares to provide the cash to pay the bills from the company. So there is no benefit to LP to keep the share price down. In fact, her personal share count is also being diluted, in order to pay the bills.
Additionally, the fact that Advent is willing to be paid in shares indicates... to me anyway... that they, Advent, are confident those shares will be worth more in the future.
Market Data 
Markets 
AI
